Myriad Ebit Per Revenue from 2010 to 2024

MYGN Stock  USD 15.71  0.22  1.42%   
Myriad Genetics Ebit Per Revenue yearly trend continues to be very stable with very little volatility. Ebit Per Revenue is likely to drop to -0.17. During the period from 2010 to 2024, Myriad Genetics Ebit Per Revenue quarterly data regression pattern had sample variance of  0.18 and median of  0.01. View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
(0.16)
Current Value
(0.17)
Quarterly Volatility
0.42420512
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Myriad Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Myriad Genetics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 67.5 M, Total Revenue of 414.1 M or Gross Profit of 327.5 M, as well as many indicators such as Price To Sales Ratio of 1.88, Dividend Yield of 0.22 or PTB Ratio of 1.44. Myriad financial statements analysis is a perfect complement when working with Myriad Genetics Valuation or Volatility modules.
  
Check out the analysis of Myriad Genetics Correlation against competitors.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

Latest Myriad Genetics' Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of Myriad Genetics over the last few years. It is Myriad Genetics' Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Myriad Genetics' overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Very volatile
   Ebit Per Revenue   
       Timeline  

Myriad Ebit Per Revenue Regression Statistics

Arithmetic Mean(0.04)
Geometric Mean0.14
Coefficient Of Variation(1,156)
Mean Deviation0.27
Median0.01
Standard Deviation0.42
Sample Variance0.18
Range1.7203
R-Value(0.05)
Mean Square Error0.19
R-Squared0
Significance0.85
Slope(0.01)
Total Sum of Squares2.52

Myriad Ebit Per Revenue History

2024 -0.17
2023 -0.16
2022 -0.18
2021 -0.0705
2020 -0.35
2018 0.00893
2017 0.15

About Myriad Genetics Financial Statements

Myriad Genetics investors utilize fundamental indicators, such as Ebit Per Revenue, to predict how Myriad Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Ebit Per Revenue(0.16)(0.17)

Pair Trading with Myriad Genetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Myriad Stock

  0.65A Agilent TechnologiesPairCorr
  0.91ME 23Andme HoldingPairCorr
  0.78VALN Valneva SE ADRPairCorr
  0.86JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr

Moving against Myriad Stock

  0.76MDGL Madrigal PharmaceuticalsPairCorr
  0.47RNXT RenovoRxPairCorr
  0.46KZR Kezar Life SciencesPairCorr
  0.36MLYS Mineralys Therapeutics,PairCorr
The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.
The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock:
Check out the analysis of Myriad Genetics Correlation against competitors.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.28)
Revenue Per Share
9.205
Quarterly Revenue Growth
0.112
Return On Assets
(0.05)
Return On Equity
(0.16)
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.